Production cost overrun for lanthanum carbonate orally disintegrating tablets
First written in FY2019-Q2. 2 of 3 entries say "Worsened", first in FY2019-Q3. Latest entry: FY2019.
No other company in this theme has enough history to compare yet.
- FY2019WorsenedAnnual report
「However, the segment loss was ¥331 million, compared with a loss of ¥324 million in the previous fiscal year, due in part to actual results for the lanthanum carbonate orally disintegrating tablets falling below the revised segment forecast and production costs exceeding initial expectations.」
Due in part to higher-than-expected production costs, the full-year segment loss in the pharmaceutical manufacturing and sales business widened from ¥324 million in the previous year to ¥331 million. - FY2019-Q3WorsenedAnnual report
「The segment loss was ¥370 million, compared with a loss of ¥210 million in the same period of the previous year, due in part to production costs for the lanthanum carbonate orally disintegrating tablets that were higher than initially expected.」
Higher-than-expected production costs continued, and the nine-month cumulative segment loss widened from ¥210 million in the same period of the previous year to ¥370 million. - FY2019-Q2MaterialisedAnnual report
「Sales were ¥2,017 million and the segment loss was ¥251 million, due to production costs for the lanthanum carbonate orally disintegrating tablets launched in September of the same year that were higher than initially expected.」
Higher-than-expected production costs were incurred for the lanthanum carbonate orally disintegrating tablets, with an impact of ¥251 million recorded as a segment loss in the pharmaceutical manufacturing and sales business.